UK-specific cost-effectiveness of tiotropium + olodaterol fixed-dose combination versus other LAMA + LABA combinations in patients with COPD

UK-specific cost-effectiveness of tiotropium + olodaterol fixed-dose combination versus other LAMA + LABA combinations in patients with COPD

Abigail Tebboth,1 Andrew Ternouth,1 Nuria Gonzalez-Rojas2 1Boehringer Ingelheim Ltd., Bracknell, UK; 2Boehringer Ingelheim GmBH, Ingelheim, Germany Objective: The aim of this study is to assess the cost-effectiveness of other long-acting muscarinic antagonist + long-acting β2 agonist combin...

Full description

Bibliographic Details
Main Authors: Tebboth A, Ternouth A, Gonzalez-Rojas N
Format: Article
Language:English
Published: Dove Medical Press 2016-11-01
Series:ClinicoEconomics and Outcomes Research
Subjects:
COPD
economic
cost-effectiveness
tiotropium + olodaterol
Online Access:https://www.dovepress.com/uk-specific-cost-effectiveness-of-tiotropium--olodaterol-fixed-dose-co-peer-reviewed-article-CEOR

Internet

https://www.dovepress.com/uk-specific-cost-effectiveness-of-tiotropium--olodaterol-fixed-dose-co-peer-reviewed-article-CEOR

Similar Items